648TiP Reduction of methotrexate (MTX) levels after glucarpidase in patients with diffuse large b cell lymphoma (DLBCL) at risk of central nervous system (CNS) involvement who receive cycles of HDMTX: An open-label, interventional, non-randomized, phase II, pilot, multicenter study

Abstract

CNS relapse in patients with Diffuse Large B Cell Lymphoma (DLBCL) is usually an early complication and with poor prognosis. R-CHOP, the standard treatment for DLBCL plays a minimal role preventing leptomeningeal and/or brain parenchyma relapse. Risk factors have been previously identified for this complication and high dose intravenous methotrexate (HDMTX) has been suggested as an effective strategy to prevent CNS lymphoma relapse (GELTAMO guidelines Haematologica 2017 and British guidelines BJAEM 2020).